Latest Articles and Analysis

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

CANN campaign promotes transgender leadership in HIV advocacy, affirming gender-affirming care as lifesaving.

Biden's SOTU addresses harm reduction, endorses MAT Act; limited HIV-specific programming focus.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

Copay accumulator programs block patient assistance from counting toward deductibles; HELP Copays Act needed.

Family support predicts treatment success; policy must address intimate partner violence and health outcomes.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

MAT Act removes X-waiver requirements, expanding buprenorphine access especially in rural communities.

Access Health Louisiana uses animated series and radio to educate communities on HIV, HCV, and public health.

NIH issues RFAs for Harm Reduction Network; Biden agenda targets decriminalization and safe consumption.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

Flurona co-infections highlight information challenges amid pandemic fatigue and misinformation.

CDC updates STI treatment guidelines; ACIP recommends universal adult HBV vaccination and HPV catch-up.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

New CANN leadership reflects on mentorship and maintaining advocacy legacy following Bill Arnold's passing.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.